✦ LIBER ✦

PHASE I/II STUDY OF THE TUMOUR-TARGETING HUMAN L19- IL2 MONOCLONAL ANTIBODY-CYTOKINE FUSION PROTEIN IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA

✍ Scribed by M. Johannsen; A. Roemer; J. Roigas; G. Curigliano; G. Spitaleri; L. Giovannoni; H.D. Menssen; L. Zardi; A. Milani; S. Boselli; D. Neri; F. De Braud

Book ID: 119619272
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 71 KB
Volume: 7
Category: Article
ISSN: 1569-9056
DOI: 10.1016/s1569-9056(08)60941-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I/II study of the tumour-targeting

Phase I/II study of the tumour-targeting human monoclonal antibody–cytokine fusion protein L19-TNF in patients with advanced solid tumours

✍ G. Spitaleri, R. Berardi, C. Pierantoni… 📂 Article 📅 2012 🏛 Springer-Verlag 🌐 English ⚖ 320 KB

The tumour-targeting human L19-IL2 immun

The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma

✍ Manfred Johannsen; Gianluca Spitaleri; Giuseppe Curigliano; Jan Roigas; Steffen 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 892 KB

Isolated limb perfusion with the tumor-t

Isolated limb perfusion with the tumor-targeting human monoclonal antibody–cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma

✍ Francesco Papadia; Valeria Basso; Roberto Patuzzo; Andrea Maurichi; Annabella Di 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 235 KB

Phase I/II clinical and pharmacokinetic

Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck

✍ Lars Bastholt; Lena Specht; Kenneth Jensen; Eva Brun; Annika Loft; Jørgen Peters 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 172 KB

A Phase II and Biomarker Study of Ramuci

A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer

✍ Zhu, A. X.; Finn, R. S.; Mulcahy, M.; Gurtler, J.; Sun, W.; Schwartz, J. D.; Dal 📂 Article 📅 2013 🏛 American Association for Cancer Research 🌐 English ⚖ 517 KB

9096 POSTER EGFR-targeting Chimeric Mono

9096 POSTER EGFR-targeting Chimeric Monoclonal lgG-1 Antibody Cetuximab in a Phase ll/lll Study Added Either to Gemcitabine Followed by Docetaxel or Carboplatin Plus Gemcitabine for Chemonaive Patients With Advanced Non-small Cell Lung Cancer (NSCLC) – Results of the Phase II Study Part

✍ Kortsik, C.; Schmid-Bindert, G.; Pilz, L.R.; Cicenas, S.; Eschbach, C.; Kollmeie 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 44 KB